Marginum awarded Young Innovative Companies (YIC) Funding

Kuopio, Finland, 3 November 2025—Marginum, a Finnish medical technology company specialising in fluorescence-based tissue monitoring systems, has been selected for Business Finland’s prestigious Young Innovative Companies (YIC) program, a national initiative designed to accelerate the global growth of Finland’s most promising startups. The recognition underscores Marginum’s innovative business model, rapid growth trajectory, and strong international potential.

Business Finland’s YIC program supports Finland’s most ambitious startups in scaling their business internationally. The program offers up to 1 million euros in non-dilutive funding across three performance-based phases, complemented by extensive mentoring and advisory services. The YIC program focuses on companies under five years old that demonstrate exceptional innovation, independent operations and a clear internationalisation strategy. Its goal is to drive rapid international growth by strengthening partnerships, accelerating commercialisation, and expanding market presence.

“Being selected for the YIC program is a significant recognition of our global potential,” said Samu Lehtonen MD, CEO of Marginum. “The support from Business Finland enables us to strengthen our capabilities, expand our team, and introduce the HIVEN® technology to new markets worldwide.”

Driving Finnish innovation worldwide

Marginum is a market forerunner in quantitative fluorescence-based tissue detection systems.  The company’s flagship product, the CE-marked HIVEN® device, provides surgeons with real-time, auditory feedback on traces of cancer during an operation. It is the world’s first and only intraoperative system that delivers continuous, objective feedback on the surgical fluorescence of resected tissue. This innovation supports surgeons to precisely detect tumour margins, aiming for maximal tumour removal and reducing the need for reoperations—a significant step toward improving long-term care for cancer patients.

“Marginum exemplifies the kind of ambitious, innovation-driven company that the YIC program is designed to support,” said Eija-Riitta Hämäläinen, Senior Advisor at Business Finland. “Their international growth potential and strong technological foundation make them a great fit for the program, and we look forward to supporting their journey toward global success.”

Business Finland’s YIC program is part of Finland’s national innovation strategy, which has supported over 500 Finnish startups since 2008, with more than 180 companies successfully completing all three funding phases. The program’s success in nurturing globally competitive companies demonstrates Finland’s commitment to research-driven entrepreneurship and sustainable growth.

Additional information

Samu Lehtonen MD
CEO, Marginum Ltd
samu.lehtonen@marginum.com
+358 40 579 7890

 
Marginum is a Finnish medical technology company founded in 2020 and a leading innovator in fluorescence-guided oncological surgery, developing optical tissue monitoring systems. The CE-marked HIVEN® by Marginum enables safe and efficient monitoring of tumour tissues during cancer surgery by seamlessly integrating into existing surgical workflows. Marginum’s vision is to enable surgeons worldwide to perform safer, more precise operations and ultimately improve patient survival and quality of life. www.marginum.com

Business Finland is a Finnish public organisation that offers innovation funding and growth services to Finnish companies, promotes tourism and investments, and attracts talent to Finland. Our mission is to forge Finland into the world's most attractive and competitive environment for innovations, investments, tourists and international talent. www.businessfinland.fi

Published in:

• Business Finland 2025 ‚Tehokkaampia syöpäleikkauksia Marginumin laitteella‘ https://www.businessfinland.fi/palvelut/tieto-ja-neuvonta/tietopankki/caset/2025/tehokkaampia-syopaleikkauksia-marginumin-laitteella/